Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 26 Feb 2020 |
| Capital Increase in Genmab as a Result of Employee Warrant Exercise | 25 Feb 2020 |
| Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons | 25 Feb 2020 |
| U.S. FDA Filing Acceptance and Priority Review for sBLA, Submitted by Novartis, for Ofatumumab in Relapsing Multiple Sclerosis | 24 Feb 2020 |
| Genmab Board of Directors Chairman to Step Down | 21 Feb 2020 |
| Genmab Publishes 2019 Annual Report | 19 Feb 2020 |